Clinical trial
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Foot Ulcer With and Without Peripheral Arterial Disease.
NCT02264288 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Foot Ulcer With and Without Peripheral Arterial Disease.
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 23, 2014
- Completion date
- February 27, 2018
- Enrollment
- 159 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.